Pathological Complete Response to Neoadjuvant Chemoimmunotherapy for Early Triple-Negative Breast Cancer: An Updated Meta-Analysis.
atezolizumab
breast cancer
durvalumab
immune checkpoint inhibitors
immunotherapy
neoadjuvant
pembrolizumab
Journal
Cells
ISSN: 2073-4409
Titre abrégé: Cells
Pays: Switzerland
ID NLM: 101600052
Informations de publication
Date de publication:
07 06 2022
07 06 2022
Historique:
received:
19
04
2022
revised:
01
06
2022
accepted:
06
06
2022
entrez:
24
6
2022
pubmed:
25
6
2022
medline:
28
6
2022
Statut:
epublish
Résumé
Immune checkpoint inhibitors (ICIs) have made a breakthrough in the systemic treatment for metastatic triple-negative breast cancer (TNBC) patients. However, results of phase II and III clinical trials assessing ICIs plus chemotherapy as neoadjuvant treatment were controversial and conflicting. We performed a meta-analysis aimed at assessing the Odds Ratio (OR) of the pathological complete response (pCR) rate in trials assessing neoadjuvant chemoimmunotherapy in TNBC. According to our results, the use of neoadjuvant chemoimmunotherapy was associated with higher pCR (OR 1.95; 95% Confidence Intervals, 1.27-2.99). In addition, we highlighted that this benefit was observed regardless of PD-L1 status since the analysis reported a statistically significant and clinically meaningful benefit in both PD-L1 positive and PD-L1 negative patients. These findings further support the exploration of the role of ICIs plus chemotherapy in early-stage TNBC, given the potentially meaningful clinical impact of these agents. Further studies aimed at more deeply investigating this emerging topic in breast cancer immunotherapy are warranted.
Identifiants
pubmed: 35740985
pii: cells11121857
doi: 10.3390/cells11121857
pmc: PMC9221459
pii:
doi:
Substances chimiques
B7-H1 Antigen
0
Types de publication
Journal Article
Meta-Analysis
Review
Langues
eng
Sous-ensembles de citation
IM
Références
Clin Cancer Res. 2018 Feb 1;24(3):511-520
pubmed: 28801472
JAMA Oncol. 2020 May 1;6(5):676-684
pubmed: 32053137
Lancet. 2020 Dec 5;396(10265):1817-1828
pubmed: 33278935
BMC Med. 2019 May 9;17(1):90
pubmed: 31068190
Expert Opin Investig Drugs. 2022 Jun;31(6):557-565
pubmed: 34802383
Ann Oncol. 2022 May;33(5):534-543
pubmed: 35182721
Ann Oncol. 2021 Aug;32(8):994-1004
pubmed: 34219000
N Engl J Med. 2020 Feb 27;382(9):810-821
pubmed: 32101663
Nat Rev Clin Oncol. 2016 Nov;13(11):674-690
pubmed: 27184417
Expert Rev Anticancer Ther. 2020 Mar;20(3):151-158
pubmed: 32067545
Cancer Immunol Immunother. 2021 Mar;70(3):607-617
pubmed: 33015734
Lancet. 2020 Oct 10;396(10257):1090-1100
pubmed: 32966830
J Natl Compr Canc Netw. 2020 Apr;18(4):479-489
pubmed: 32259782
Arch Gynecol Obstet. 2016 Feb;293(2):247-69
pubmed: 26341644
Lancet. 2021 May 8;397(10286):1750-1769
pubmed: 33812473
Bioorg Med Chem. 2020 May 1;28(9):115434
pubmed: 32222339
Cochrane Database Syst Rev. 2019 Oct 3;10:ED000142
pubmed: 31643080
Drug Resist Updat. 2017 May;32:1-15
pubmed: 29145974
Crit Rev Oncol Hematol. 2021 Mar;159:103223
pubmed: 33482345
N Engl J Med. 2020 May 14;382(20):1894-1905
pubmed: 32402160
Ann Oncol. 2020 Nov;31(11):1526-1535
pubmed: 32828825
BMJ. 2009 Jul 21;339:b2535
pubmed: 19622551
Expert Opin Investig Drugs. 2022 Apr;31(4):415-423
pubmed: 34429006
F1000Res. 2019 Aug 2;8:
pubmed: 31448088
N Engl J Med. 2018 May 31;378(22):2078-2092
pubmed: 29658856
BMJ. 2011 Oct 18;343:d5928
pubmed: 22008217
N Engl J Med. 2017 Aug 10;377(6):523-533
pubmed: 28578601
Ann Oncol. 2019 Aug 1;30(8):1279-1288
pubmed: 31095287
JAMA Oncol. 2019 Jan 1;5(1):74-82
pubmed: 30242306
Immunotherapy. 2017 Sep;9(11):913-927
pubmed: 29338609